Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

Inclusion Criteria:

* Previously untreated non-cutaneous peripheral T-cell lymphoma, including human T-cell lymphotropic virus type 1 (HTLV-1) related T-cell lymphoma, and natural killer (NK)-cell lymphoma.
* Ages 18 to 65 years.
* Life expectancy \> 3 months.
* Written informed consent.

Exclusion Criteria:

* B-cell lymphoma or other subtype of T-cell lymphoma including anaplastic large cell lymphoma AKL(+), lymphoblastic lymphoma and primary cutaneous T-cell lymphoma.
* Any previous therapy for lymphoma except for short-term corticosteroids before inclusion.
* Inability to tolerate the ACVBP regimen according to investigator's judgement.
* Positive serology for HIV.
* Poor renal function (creatinin \> 150 µmol/l within 14 days before enrollment), poor liver function (total bilirubin \> 30 µmol/l, transaminases \> 2.5 upper normal limit \[UNL\] within 14 days before enrollment), unless these abnormalities are related to the lymphoma.
* Poor bone marrow reserve as defined by neutrophils \< 1.5 G/l or platelets \< 100 G/l within 14 days before enrollment, unless these abnormalities are related to the lymphoma.
* Patient with \>= grade 2 peripheral neuropathy non-related to lymphoma.
* Any central nervous system (CNS) disease.
* CNS or meningeal involvement by the lymphoma.
* Any serious active disease or comorbidity according to the investigator's decision.
* Any history of cancer during the last 5 years with the exception of non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma.
* Known hypersensitivity to bortezomib, boron or mannitol.
* Contraindication to any cytotoxic drug contained in chemotherapy regimen.
* Pregnant or lactating women or women of childbearing potential not willing to use an adequate method of birth control (i.e. hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of study.
* Men not agreeing to take adequate contraceptive precautions during the study.
* Treatment with investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
* Adult patient under tutelage.